Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group.
Qi SN, Li YX, Specht L, Oguchi M, Tsang R, Ng A, Suh CO, Ricardi U, Mac Manus M, Dabaja B, Yahalom J.
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1064-1081. doi: 10.1016/j.ijrobp.2021.02.011. Epub 2021 Feb 11.
PMID:33581262
Extranodal T- and NK-cell lymphomas.
de Leval L, Feldman AL, Pileri S, Nakamura S, Gaulard P.
Virchows Arch. 2023 Jan;482(1):245-264. doi: 10.1007/s00428-022-03434-0. Epub 2022 Nov 7.
PMID:36336765
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
Ghione P, Qi S, Imber BS, Seshan V, Moskowitz A, Galasso N, Lunning M, Straus D, Sauter C, Dahi P, Dogan A, Yahalom J, Horwitz S.
Leuk Lymphoma. 2020 Dec;61(14):3331-3341. doi: 10.1080/10428194.2020.1811864. Epub 2020 Aug 26.
PMID:32844695
Review on natural killer/T-cell lymphoma.
He X, Gao Y, Li Z, Huang H.
Hematol Oncol. 2023 Apr;41(2):221-229. doi: 10.1002/hon.2944. Epub 2021 Dec 9.
PMID:34731509
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.
J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.